See more : Oryx International Growth Fund Limited (OIG.L) Income Statement Analysis – Financial Results
Complete financial analysis of Kindred Biosciences, Inc. (KIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kindred Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Anteris Technologies Ltd (AMEUF) Income Statement Analysis – Financial Results
- BIJOY HANS LTD. (BIJHANS.BO) Income Statement Analysis – Financial Results
- Bestec Power Electronics Co., Ltd. (3308.TW) Income Statement Analysis – Financial Results
- The AES Corporation (0H6G.L) Income Statement Analysis – Financial Results
- Mehai Technology Limited (MEHAI.BO) Income Statement Analysis – Financial Results
Kindred Biosciences, Inc. (KIN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.kindredbio.com
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.16M | 4.26M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.63M | 587.00K | 324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.54M | 3.67M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.03% | 86.21% | 83.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.28M | 28.31M | 26.40M | 17.67M | 13.86M | 19.41M | 18.69M | 3.14M | 75.00K |
| General & Administrative | 21.98M | 37.93M | 22.08M | 11.90M | 6.84M | 6.86M | 8.54M | 1.08M | 45.00K |
| Selling & Marketing | 0.00 | 0.00 | 4.42M | 2.08M | 1.47M | 992.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.98M | 37.93M | 26.50M | 13.99M | 8.31M | 7.85M | 8.54M | 1.08M | 45.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.26M | 66.24M | 52.90M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Cost & Expenses | 57.89M | 66.82M | 53.22M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Depreciation & Amortization | 4.68M | 2.54M | 805.00K | 475.00K | 155.00K | 146.00K | 58.00K | 3.13K | 0.00 |
| EBITDA | -15.29M | -58.85M | -48.89M | -30.40M | -22.34M | -26.98M | -27.08M | -4.21M | -120.00K |
| EBITDA Ratio | -36.27% | -1,382.75% | -2,486.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.97M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Operating Income Ratio | -47.36% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -56.00 | 0.00 |
| Income Before Tax | -21.80M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Income Before Tax Ratio | -51.69% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Net Income | -23.62M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Net Income Ratio | -56.03% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| EPS Diluted | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| Weighted Avg Shares Out | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
| Weighted Avg Shares Out (Dil) | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
Edited Transcript of KIN earnings conference call or presentation 16-Mar-20 8:30pm GMT
Q4 2019 Kindred Biosciences Inc Earnings Call
-$0.41 EPS Expected for Kindred Biosciences Inc (NASDAQ:KIN) This Quarter
Brokerages expect Kindred Biosciences Inc (NASDAQ:KIN) to announce ($0.41) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Kindred Biosciences’ earnings. The lowest EPS estimate is ($0.43) and the highest is...
Prudential Financial Inc. Buys Shares of 19,329 Kindred Biosciences Inc (NASDAQ:KIN)
Prudential Financial Inc. bought a new stake in Kindred Biosciences Inc (NASDAQ:KIN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 19,329 shares of the biopharmaceutical company’s stock, valued...
Bank of Montreal Can Has $55,000 Position in Kindred Biosciences Inc (NASDAQ:KIN)
Bank of Montreal Can increased its position in Kindred Biosciences Inc (NASDAQ:KIN) by 99.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,474 shares of the biopharmaceutical company’s stock after acquiring an additional 3,229 shares during the period....
Brokerages Anticipate Kindred Biosciences Inc (NASDAQ:KIN) Will Post Quarterly Sales of $1.75 Million
Wall Street analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to announce sales of $1.75 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Kindred Biosciences’ earnings, with the lowest sales estimate coming in at...
Lawrence Livermore Lab Uses Artificial Intelligence and Supercomputers in Global Fight Against COVID-19
Lawrence Livermore National Laboratory (LLNL) scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics, and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease. B
Lab antibody, antiviral research aids COVID-19 response
Lawrence Livermore National Laboratory (LLNL) scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates ...
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) Arcutis Biotherapeutics...
Recent Analysts' Ratings Changes for Kindred Biosciences (KIN)
Kindred Biosciences (NASDAQ: KIN) has recently received a number of price target changes and ratings updates: 3/18/2020 – Kindred Biosciences was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 3/17/2020 – Kindred Biosciences had its...
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) Arcutis Biotherapeutics...
Source: https://incomestatements.info
Category: Stock Reports